Effects of semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease: rationale and design of the STRIDE trial

赛马鲁肽 医学 狼牙棒 安慰剂 2型糖尿病 间歇性跛行 内科学 不利影响 临床终点 随机对照试验 糖尿病 物理疗法 动脉疾病 内分泌学 血管疾病 利拉鲁肽 心肌梗塞 替代医学 病理 传统PCI
作者
Henrik Sillesen,E. Sebastian Debus,R B B Enggaard,Ofir Frenkel,Yuval Heled,Samreen Mansor-Lefebvre,Marc P. Bonaca
出处
期刊:European Heart Journal [Oxford University Press]
卷期号:42 (Supplement_1) 被引量:3
标识
DOI:10.1093/eurheartj/ehab724.2027
摘要

Abstract Background/Introduction Lower extremity peripheral arterial disease (PAD) is a severe form of atherosclerotic cardiovascular (CV) disease. The classical symptom is intermittent claudication (IC), associated with limited walking ability and poor health-related quality of life (QoL). Type 2 diabetes (T2D) is one of the leading causes of PAD; ∼30% of patients with PAD have T2D. While anti-atherosclerotic drugs and lifestyle changes are recommended, there are no effective drugs to specifically improve functional outcomes in PAD and T2D. Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved as an adjunct to diet and exercise for glycaemic control in patients with T2D. In the T2D SUSTAIN clinical trial programme, once-weekly (OW) subcutaneous semaglutide 0.5 and 1.0 mg was superior for glycaemic control and weight loss vs placebo and a range of approved antidiabetic drugs. In SUSTAIN 6, a dedicated CV outcomes trial, OW semaglutide resulted in a 26% reduction in three-point major adverse CV events (MACE) compared with placebo in patients with T2D at high CV risk, leading to its approval for MACE risk reduction in those with T2D and CV disease in the USA. Evidence suggests this may be partly attributable to the anti-inflammatory and anti-atherosclerotic effects of semaglutide, which may also apply to PAD. Purpose The STRIDE trial will demonstrate the effect of OW semaglutide 1.0 mg vs placebo on walking ability in patients with T2D and PAD with IC. Methods STRIDE is a 52-week, randomised, double-blind, placebo-controlled, phase 3b trial. Trial design and eligibility criteria are shown in the Figure; ∼800 patients will be randomised 1:1 to OW semaglutide 1.0 mg or placebo, both added to standard of care. The primary endpoint is change in maximum walking distance on a constant load treadmill test from baseline to week 52. Secondary confirmatory endpoints include changes in pain-free walking distance and PAD-specific, health-related patient-reported outcomes (Vascular QoL Questionnaire-6) from baseline to week 52. Results The trial started in October 2020 and is currently recruiting, with ∼120 sites in ∼20 countries across Asia, Europe, and North America. Conclusion STRIDE is the first and only dedicated PAD outcomes trial with a GLP-1RA and thus presents a unique trial design. While major adverse limb events typically occur in the later stages of PAD, STRIDE instead measures the effect of OW semaglutide on functional outcomes such as walking ability and QoL, which affect everyday living in patients with PAD and IC. STRIDE data will provide important clinical insights regarding the role of OW semaglutide in patients with T2D and PAD. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): Novo Nordisk A/S

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
刚刚
Owen的应助被黑皮鞋采纳,获得10
刚刚
心理学小学生完成签到,获得积分10
刚刚
Code_king发布了新的文献求助10
刚刚
刚刚
Code_king发布了新的文献求助10
刚刚
刚刚
黃偉倫发布了新的文献求助10
刚刚
共享精神的应助被云墨采纳,获得10
1秒前
高挑的鱼完成签到 ,获得积分10
1秒前
1秒前
在水一方的应助被11采纳,获得30
1秒前
molihuakai的应助被jerrychen采纳,获得10
1秒前
Jasper的应助被xiaomings007采纳,获得10
1秒前
2秒前
NexusExplorer的应助被煎饼煎饼采纳,获得10
2秒前
下一秒的王的应助被可靠吐司采纳,获得10
2秒前
curry完成签到,获得积分10
3秒前
xliang完成签到,获得积分10
3秒前
51515发布了新的文献求助10
3秒前
3秒前
彭于晏的应助被大刘采纳,获得10
3秒前
英姑的应助被yimeng采纳,获得10
4秒前
欢呼的梦蕊完成签到,获得积分10
4秒前
balalal发布了新的文献求助10
4秒前
4秒前
4秒前
爆米花的应助被11122采纳,获得10
4秒前
4秒前
5秒前
5秒前
5秒前
5秒前
缓慢半山发布了新的文献求助10
5秒前
知性的书文的应助被xh采纳,获得10
6秒前
柚一完成签到,获得积分10
6秒前
laruae发布了新的文献求助10
6秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176102
求助须知:如何正确求助?哪些是违规求助? 9567588
关于积分的说明 21793477
捐赠科研通 7770603
什么是DOI,文献DOI怎么找? 3431969
关于科研通互助平台的介绍 2556294
邀请新用户注册赠送积分活动 2477522